SymBio Pharmaceuticals Limited Overview
Get informed when a big investor buys or sells
+ Follow1062.30%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
SymBio Pharmaceuticals Limited's return on equity stands at 1062.3%. That is above the sector sector average of 11.85%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
SymBio Pharmaceuticals Limited sits higher the its sector benchmark (11.85%) with a ROE of 1062.3%. That is roughly 8862.9% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of 1062.3% for SymBio Pharmaceuticals Limited means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how SymBio Pharmaceuticals Limited's ROE evolved across reporting periods, while the comparison chart places SYMQY next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
